This trial is evaluating whether MK-2060 will improve 1 primary outcome and 4 secondary outcomes in patients with Kidney Failure, Chronic. Measurement will happen over the course of From date of randomization until the date of first occurrence of an AVG thrombosis event, assessed up to approximately 17 months.
This trial requires 489 total participants across 3 different treatment groups
This trial involves 3 different treatments. MK-2060 is the primary treatment being studied. Participants will be divided into 2 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
"Results from a recent paper of our study suggest that curing kidney diseases is not possible as they are for other diseases. In order to attain cure, further studies would be useful." - Anonymous Online Contributor
"Around 1 million Americans are diagnosed with kidney diseases each year, and over 17 million have one or more chronic kidney conditions. About 35,000 Americans die of kidney disease every year. Most deaths occur among African-Americans, Asians, Latinos, Hispanics, and Native Americans; most African-Americans have chronic kidney diseases." - Anonymous Online Contributor
"Many kidney diseases are first noticed when symptoms do not respond to typical treatments. In most of the kidney diseases, initial symptoms remain unexplained. A complete physical examination will identify signs which are easy to remember and indicate severity of the condition. Some of the signs are specific to particular kidney diseases. Patients with protein in the urine, e.g. nephrolithiasis, hematuria and proteinuria require further examination." - Anonymous Online Contributor
"It is widely recognized that a disease can be diagnosed correctly when the patient exhibits a set of the following criteria (i.e., classic manifestation of the disease): a) a significant increase in creatinine values in a healthy patient (e.g., 0.2-µmol/l) (2.5 mL/min); b) a decrease in creatinine values to 0." - Anonymous Online Contributor
"Treatment for kidney disease is based upon the presence of the disease, the type and severity of the disease as well as the age of patient. Patients diagnosed with diabetic nephropathy may require ACE inhibitors, angiotensin antagonists, or angiotensin receptor antagonists. Patients with the end stage kidney diseases require dialysis. Patients suspected to have kidney disease should undergo examination by a physician. For example, patients with high blood pressure and enlarged spleen or/and liver should undergo laboratory test. The key determinants in the treatment of kidney disorder include level of control of blood pressure and the choice of medications." - Anonymous Online Contributor
"The data suggest that kidney disease is often multifactorial and related to factors inherent in the individual, to the environment and to the society. The present data should initiate a comprehensive approach to prevention and treatment of kidney disease." - Anonymous Online Contributor
"Recent findings for the first time provides evidence that MK-2060 can improve the quality of life in patients with chronic kidney disease and provides a framework for how to proceed with future, larger, trials to understand whether topical MK-2060 can ameliorate the severity of chronic kidney disease in patients with chronic kidney disease." - Anonymous Online Contributor
"Mk-2060 is a new drug that has been developed by Microkinetics and has the potential to be efficacious as a novel therapeutically active agent in the treatment of nephrotic syndrome. In vitro, Mk-2060 can inhibit the pro-inflammatory effects of TNF-alpha, as well as the pro-fibrinolytic activity of Tissue Factor." - Anonymous Online Contributor
"[Treatment of kidney diseases is important for the preservation of the function of the kidneys and reduction of the risk of irreversible damage in later stages. This is especially true for high blood pressure with proteinuria as a result of which the progression of the disease is fast, and the need for dialysis is high.] (http://www.kidney.org/content/115/5/2211) question: Is type A personality associated with subclinical cardiovascular disease in non-diabetic adults? answer: Type A personality is strongly associated with subclinical CVD in non-diabetic individuals. Although more research is needed, this finding supports evidence that high BP may precede the onset of the disease." - Anonymous Online Contributor
"Currently, [many therapies are used to treat kidney disease and there is still great need for research in kidney disease (Cicatrix) and nephrology (Nephrology) in general. (https://www.ncbi.nlm.nih.gov/books/NBK351159." - Anonymous Online Contributor
"Data from a recent study suggest the kidney diseases seem to run on family lines in the Chinese population. Therefore, the risk of development of a specific disease in an affected relative should be considered during genetic counselling." - Anonymous Online Contributor
"Currently MK-2060 is used alongside conventional treatment for patients with advanced cancer. There has not been much analysis of the optimal dosing regimen for cancer yet many groups are using a fixed dose and it has not been studied in cancer in more than 1 dosing schedule. This is one of the many reasons that the European Medicines Agency have declared a need for more safety and efficacy data on MK-2060. For the treatment of kidney tumors, MK-2040 should also be considered to be dosed in a titration style with minimal fixed doses as a step to minimising toxicity and side effects. These therapies should be considered in the context of nephron sparing and renal toxicity." - Anonymous Online Contributor